Actavia Life Sciences, Inc.
RASP · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Market Cap | $11,560 | $838 | $4,134 | $5,168 |
| - Cash | $75 | $39 | $11 | $14 |
| + Debt | $211 | $220 | $592 | $522 |
| Enterprise Value | $11,696 | $1,018 | $4,716 | $5,676 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$0 | -$2 |
| % Margin | – | – | – | – |
| EBITDA | -$380 | $255 | -$247 | -$555 |
| % Margin | – | – | – | – |
| Net Income | -$4,443 | -$687 | -$876 | -$5,347 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.008 | -0.006 | -0.013 | -0.078 |
| % Growth | -24.2% | 51.2% | 83.6% | – |
| Operating Cash Flow | -$9 | -$313 | -$293 | -$251 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$9 | -$313 | -$293 | -$251 |